​

Acadia Pharmaceuticals (ACAD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ACAD Stock Forecast

Acadia Pharmaceuticals (ACAD) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $29.95, with a high of $37.00 and a low of $14.50. This represents a 51.80% increase from the last price of $19.73.

$10 $16 $22 $28 $34 $40 High: $37 Avg: $29.95 Low: $14.5 Last Closed Price: $19.73

ACAD Stock Rating

Acadia Pharmaceuticals stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 25 Buy (67.57%), 11 Hold (29.73%), 1 Sell (2.70%), and 0 Strong Sell (0.00%).

Buy
Total 37 1 11 25 Strong Sell Sell Hold Buy Strong Buy

ACAD Price Target Upside V Benchmarks

TypeNameUpside
StockAcadia Pharmaceuticals51.80%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts61430
Avg Price Target$31.50$32.04$33.18
Last Closing Price$19.73$19.73$19.73
Upside/Downside59.66%62.39%68.17%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2641141-20
Sep, 2641241-21
Aug, 2641241-21
Jul, 2641241-21
Jun, 2641241-21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 13, 2026UBS$23.00$19.4118.50%16.57%
Sep 28, 2026William Blair$33.00$20.6859.57%67.26%
Sep 25, 2026Ananda GhoshH.C. Wainwright$33.00$21.0356.92%67.26%
Sep 25, 2026David HoangDeutsche Bank$31.00$21.4144.79%57.12%
Sep 25, 2026BMO Capital$34.00$22.1853.29%72.33%
Sep 25, 2026Ami FadiaNeedham$35.00$22.1857.80%77.39%
Aug 25, 2026Deutsche Bank$38.00$30.3125.37%92.60%
Aug 25, 2026Morgan Stanley$28.00$29.65-5.56%41.92%
Aug 17, 2026UBS$49.00$28.2473.51%148.35%
Aug 12, 2026Ami FadiaNeedham$41.00$29.4139.41%107.81%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026UBSBuyNeutraldowngrade
Oct 05, 2026RBC CapitalOutperformOutperformhold
Sep 25, 2026H.C. WainwrightBuyBuyhold
Sep 25, 2026Deutsche BankBuyBuyhold
Sep 25, 2026NeedhamBuyBuyhold
Sep 25, 2026CitigroupMarket OutperformMarket Outperformhold
Sep 24, 2026CitigroupBuyBuyhold
Sep 24, 2026Cowen & Co.BuyBuyhold
Sep 24, 2026BMO CapitalOutperformOutperformhold
Sep 23, 2026OppenheimerPerformPerformhold

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.05$-1.34$-0.37$1.37----
Avg Forecast$-1.02$-1.32$-0.36$0.72$0.75$1.12$1.67$2.18
High Forecast$-0.94$-1.25$-0.07$1.21$1.19$2.27$2.78$2.32
Low Forecast$-1.08$-1.42$-0.47$0.43$0.24$0.43$0.11$2.07
Surprise %2.94%1.52%2.78%90.28%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$484.14M$517.24M$726.44M$957.80M----
Avg Forecast$487.98M$514.79M$719.17M$969.65M$1.05B$1.17B$1.30B$1.44B
High Forecast$509.14M$546.26M$723.91M$975.90M$1.09B$1.18B$1.31B$1.51B
Low Forecast$458.75M$496.61M$709.72M$964.06M$1.02B$1.17B$1.29B$1.39B
Surprise %-0.79%0.47%1.01%-1.22%----

Net Income Forecast

$-350M $-180M $-10M $160M $330M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-167.87M$-215.97M$-61.29M$226.45M----
Avg Forecast$-187.72M$-252.14M$-61.29M$128.51M$134.26M$208.81M$282.56M$357.29M
High Forecast$-150.18M$-201.71M$-49.03M$197.58M$194.99M$371.62M$455.51M$379.72M
Low Forecast$-225.27M$-302.57M$-73.54M$70.93M$38.68M$71.02M$18.15M$339.05M
Surprise %-10.58%-14.34%-76.22%----

ACAD Forecast FAQ

Is Acadia Pharmaceuticals stock a buy?

Acadia Pharmaceuticals stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 25 Buy, 11 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Acadia Pharmaceuticals is a favorable investment for most analysts.

What is Acadia Pharmaceuticals's price target?

Acadia Pharmaceuticals's price target, set by 37 Wall Street analysts, averages $29.95 over the next 12 months. The price target range spans from $14.5 at the low end to $37 at the high end, suggesting a potential 51.80% change from the previous closing price of $19.73.

How does Acadia Pharmaceuticals stock forecast compare to its benchmarks?

Acadia Pharmaceuticals's stock forecast shows a 51.80% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Acadia Pharmaceuticals over the past three months?

  • October 2026: 20.00% Strong Buy, 55.00% Buy, 20.00% Hold, 5.00% Sell, 0% Strong Sell.
  • September 2026: 19.05% Strong Buy, 57.14% Buy, 19.05% Hold, 4.76% Sell, 0% Strong Sell.
  • August 2026: 19.05% Strong Buy, 57.14% Buy, 19.05% Hold, 4.76% Sell, 0% Strong Sell.

What is Acadia Pharmaceuticals’s EPS forecast?

Acadia Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $0.75, marking a -45.26% decrease from the reported $1.37 in 2024. Estimates for the following years are $1.12 in 2026, $1.67 in 2027, and $2.18 in 2028.

What is Acadia Pharmaceuticals’s revenue forecast?

Acadia Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $1.05B, reflecting a 10.06% increase from the reported $957.8M in 2024. The forecast for 2026 is $1.17B, followed by $1.3B for 2027, and $1.44B for 2028.

What is Acadia Pharmaceuticals’s net income forecast?

Acadia Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $134.26M, representing a -40.71% decrease from the reported $226.45M in 2024. Projections indicate $208.81M in 2026, $282.56M in 2027, and $357.29M in 2028.